US20030059843A1 - High throughput screening of ligand binding to macromolecules using high resolution powder diffraction - Google Patents
High throughput screening of ligand binding to macromolecules using high resolution powder diffraction Download PDFInfo
- Publication number
- US20030059843A1 US20030059843A1 US10/160,367 US16036702A US2003059843A1 US 20030059843 A1 US20030059843 A1 US 20030059843A1 US 16036702 A US16036702 A US 16036702A US 2003059843 A1 US2003059843 A1 US 2003059843A1
- Authority
- US
- United States
- Prior art keywords
- ligands
- powder diffraction
- high resolution
- sample
- sample slurry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 99
- 229920002521 macromolecule Polymers 0.000 title claims abstract description 73
- 239000000843 powder Substances 0.000 title claims abstract description 64
- 238000013537 high throughput screening Methods 0.000 title claims abstract description 5
- 239000002002 slurry Substances 0.000 claims abstract description 62
- 239000000463 material Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000008569 process Effects 0.000 claims abstract description 22
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 16
- 238000002447 crystallographic data Methods 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 34
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 102100033468 Lysozyme C Human genes 0.000 description 24
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 24
- 108010014251 Muramidase Proteins 0.000 description 23
- 229960000274 lysozyme Drugs 0.000 description 22
- 235000010335 lysozyme Nutrition 0.000 description 22
- 239000004325 lysozyme Substances 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000013078 crystal Substances 0.000 description 17
- 239000000872 buffer Substances 0.000 description 12
- 230000003993 interaction Effects 0.000 description 11
- 238000012216 screening Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000013459 approach Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000009918 complex formation Effects 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 108010029165 Metmyoglobin Proteins 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000003991 Rietveld refinement Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00599—Solution-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00702—Processes involving means for analysing and characterising the products
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/08—Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creation; Particular methods of cleavage from the liquid support
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N2015/0096—Investigating consistence of powders, dustability, dustiness
Definitions
- the present invention relates to a process for detecting or screening possible interactions between a selected target macromolecule or protein and one or more possible ligands, e.g., small molecule ligands.
- the present invention provides a process for the evaluation of the binding of ligands to macromolecules using high resolution powder diffraction data including producing a first sample slurry of a selected polycrystalline macromolecule material and a solvent, producing a second sample slurry of a selected polycrystalline macromolecule material, one or more ligands and said solvent, obtaining a high resolution powder diffraction pattern on each of said first sample slurry and said second sample slurry, and, comparing the high resolution powder diffraction pattern of said first sample slurry and the high resolution powder diffraction pattern of said second sample slurry whereby a difference in the high resolution powder diffraction patterns of said polycrystalline macromolecule material in said first sample slurry and said polycrystalline macromolecule material in said second sample slurry beyond expected or measured experimental error provides a positive indication for the formation of a complex between said selected polycrystalline macromolecule material and at least one of said one or more ligand
- experimental error is meant the well-understood uncertainties associated with experimentation in general, defined as the variability between observations from experimental units that have been treated identically, including but not limited to such factors as human error, instrument limitations, variations in reagents, errors due to external influences (such as light, heat, dust, etc.), sampling errors, sample variation, and changes in samples based on carrying out an experiment, and the fact that not all measurements have well- or perfectly-defined values.
- the present invention further provides a process of screening, including high throughput screening, of binding of ligands to macromolecules using high resolution powder diffraction data including producing a sample slurry mixture including a selected polycrystalline macromolecule material, a solvent, and a mixture of N ligands, obtaining a high resolution powder diffraction pattern of said sample slurry mixture, comparing the high resolution powder diffraction pattern of said polycrystalline macromolecule material in said sample slurry mixture with a reference of a high resolution powder diffraction pattern of said selected polycrystalline macromolecule material in the absence of any ligands whereby a difference in the high resolution powder diffraction patterns of said polycrystalline macromolecule material in said sample slurry mixture and said selected polycrystalline macromolecule material in the absence of any ligands beyond expected or measured experimental error provides a positive indication for the formation of a complex between said selected polycrystalline macromolecule material and at least one of said mixture of N ligands, dividing said mixture of N ligands into at least two sample s
- the present invention concerns a process that can be used to detect or screen possible interactions between a selected target macromolecule or protein and one or more possible ligands, including small molecule ligands.
- Certain macromolecules in nature are known to interact with other molecules having a specific 3-dimensional spatial and electronic distribution. Any macromolecule having such specificity can be considered a receptor, whether the macromolecule is an enzyme, a protein, a glycoprotein, an antibody, or an oligonucleotide sequence of DNA, RNA, or the like.
- the various molecules that associate with such receptors are known as ligands.
- Small molecule ligands are generally understood to be molecules on the order of about 5,000 Daltons or smaller in size and may be, for example, an organic molecule or a piece or fragment of a larger ligand, such as an antigen or antibody.
- the indication for this interaction or binding is a change in a high resolution powder diffraction pattern of the target protein or macromolecule as compared to the unbound form of the target protein or macromolecule which is the result of a modification of its crystal structure upon formation of a protein-ligand complex.
- the comparison between patterns can be of the positions of diffraction peaks in the two patterns.
- the process is a search approach in which tests of the binding between the target protein or macromolecule and a sequence of ligand mixtures is then used as a rapid means of identifying those ligands that bind to the target protein or macromolecule.
- One approach can be a binary search approach.
- the screening method of the present invention can be as follows. Two samples of polycrystalline material are produced as slurries.
- slurry is meant, for example, a suspension of microcrystals of a macromolecule or macromolecule-ligand complex in a liquid.
- One of the samples includes the target protein or macromolecule and a suitable solvent.
- the other of the samples includes the target protein or macromolecule, one or more selected ligands and the same solvent as in the first sample.
- High resolution powder diffraction patterns are obtained for the polycrystalline macromolecule material in each sample. The patterns from the first and second samples are then compared to see if there is any discernable difference between the two sets of diffraction patterns beyond expected or measured experimental error or variation.
- the pattern of the first sample can be inspected or analyzed to determine the positions of the diffraction peaks from the unbound form of the target protein or macromolecule, while the pattern of the second sample can be inspected or analyzed to determine the positions of the diffraction peaks from the target protein or macromolecule in the presence of the one or more selected ligands. Differences in such diffraction peaks can then be used to determine if there is a difference indicating binding of a ligand. This process is readily automated via computerized data processing routines.
- a more detailed screening process for a larger suite of ligands and a single target protein or macromolecule could be as follows.
- Such a screening process can be a binary search approach as follows or may be other than a binary approach, i.e., division can be into as many sample slurries as desired.
- a mixture of “N” ligands is produced in a single solution.
- a target protein or macromolecule is then exposed to the single solution of ligands thereby producing a slurry of polycrystalline material.
- a screening procedure is conducted wherein high resolution powder diffraction patterns are obtained for the sample.
- the diffraction pattern is then compared to a reference diffraction pattern from a sample of the unbound form of the target protein or macromolecule.
- a reference diffraction pattern from a sample of the unbound form of the target protein or macromolecule.
- Powder diffraction from polycrystalline slurries is far more robust because the experimental conditions (solvent pH, ion concentration and the like) for obtaining polycrystalline material is much broader and can be more tightly controlled than for growing large single crystals.
- crystal fracture during protein-ligand formation is essentially irrelevant in a powder diffraction experiment as the material is polycrystalline.
- This invention should be useful for screening potential pharmaceutical materials for binding to a protein that was previously identified as a crucial component in a target organism (human, bacterial, viral, etc.). Following this identification of potential activity, further studies can be pursued to determine the usefulness of this material as a drug.
- this invention can be used to identify the mode or modes of action for a particular protein by exposing it to a suite of ligands that encompass its possible modes of action. Then, the mode of interaction can be determined by, e.g., examining the results from a single crystal diffraction study of a crystal grown of the protein-ligand complex.
- Powder diffraction may be a useful tool for examining protein structures. Powder diffraction patterns can display considerable sensitivity to subtle structural changes via shifts in the diffraction peak positions and changes in intensity. Such studies showed that protein lattice parameter determinations from powder data are perhaps two orders of magnitude more precise than those obtained from typical single crystal experiments and that combined Rietveld refinements (see Rietveld, J. Appl. Crys., vol. 2, pp. 65-71 (1969) and stereochemical restraint refinements can give protein structures of moderate ( ⁇ 3 ⁇ ) resolution.
- the lattice parameters of lysozyme and ( ⁇ -NAG/lysozyme complex have been determined with unprecedented precision via powder diffraction.
- the precision obtained here approaches one part in 80,000 and is the result of Rietveld refinement fitting of the entire powder diffraction profile and the extreme sharpness of the peaks.
- Similar precision was obtained in earlier powder diffraction studies of metmyoglobin and Zn insulin complexes (see Von Dreele, J. Appl. Cryst., vol. 32, pp. 1084-1089 (1999) and Von Dreele et al., Acta Cryst., vol. D56, pp. 1549-1553 (2000)).
- polycrystalline lysozyme and NAG/lysozyme powders prepared in this case by rapid precipitation, consist of essentially defect free crystallites that are a few microns across.
- crystallites are only a few hundred protein unit cells in extent which, when coupled with the relatively weak binding between adjacent molecules, is insufficient to retain point and line defects at ambient temperature. Consequently, powder diffraction patterns of these materials give diffraction peaks that are as sharp as can be obtained from a given diffraction instrument; this may be a common feature of ambient temperature protein powder diffraction patterns.
- proteins are “perfect” powders for diffraction thus ensuring application of this invention to a wide variety of proteins.
- the extreme sharpness of these patterns arose from the uniform and easily controlled precipitation conditions and allowed easy discernment of the small structural changes associated with protein/ligand complex formation and ready discrimination from cases where no complex is formed.
- the quality of the powder diffraction pattern was sufficient to determine the detailed structural features of the protein/ligand complex.
- high-resolution powder diffraction can facilitate the screening for protein/ligand interactions and may facilitate the determination of their resulting structures under a wide variety of conditions.
- Chicken egg lysozyme (EC 3.2.1.17, FisherBiotech, 3X crystallized, lot Nos. 995417-12 and 996924-12) and N-acetylglucosamine (NAG, ICN Biomedicals, Inc. lot No. R9745), pH 6.0 0.05M Na 2 HPO 4 /KH 2 PO 4 buffer (Fisher Sci.), pH 5.0 0.05M KHphthalate/NaOH buffer (HydrionTM, Aldrich Chem.) and NaCl (“Certified for Biological Use”, Fisher Sci.) were used as received.
- a polycrystalline slurry was made by combining ⁇ 20 mg lysozyme (1.4 ⁇ mol), about 10 mg of NAG (45 ⁇ mol) and 200 ⁇ l of 0.5M NaCl pH 6.0 buffer with an agate mortar and pestle. Polycrystalline precipitate formed within a few seconds.
- the slurry was loaded into a 1.5 mm diameter glass capillary, and centrifuged to pack the slurry. Excess mother liquor was removed and the capillary flame sealed to prevent subsequent solvent evaporation.
- a polycrystalline sample of unbound lysozyme in pH 6.0 0.5M NaCl buffer was prepared. Similar samples with pH 5.0 0.5M NaCl buffer were also prepared.
Landscapes
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Abstract
Description
- This application is a continuation-in-part to U.S. patent application Ser. No. 09/871,527 filed May 31, 2001.
- [0002] This invention was made with government support under Contract No. W-7405-ENG-36 awarded by the U.S. Department of Energy. The government has certain rights in the invention.
- The present invention relates to a process for detecting or screening possible interactions between a selected target macromolecule or protein and one or more possible ligands, e.g., small molecule ligands.
- With the decoding of the human and other genomes, the paradigm of drug discovery is expected to change to one that is focused on molecular design for interaction with specific proteins. This new emphasis on proteomics will require experimental verification of the details of protein/ligand interactions under a wide variety of conditions. In general, current techniques either require formation of single crystals of sufficient quality of the protein/ligand complex for x-ray diffraction work or else interpretation of NMR spectra. This work is difficult as indicated by a cursory examination of the Protein Data Base that shows only about 10% of the entries involve protein/ligand complexes. (H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne: The Protein Data Bank. Nucleic Acids Research, 28 pp. 235-242 (2000), available on line at http://www.rcsb.org/pdb/).
- Present screening methods for protein-ligand interaction often involve either: (1) the selective displacement of a dye molecule by the ligand thus provoking a change in the optical spectrum; or (2) performance of detailed single crystal structure determinations on every potential protein-ligand complex to determine the presence or absence of the ligand molecule in the protein structure. The former method requires selection and development of a suitable dye that interacts with the protein in the same way a presumed ligand might interact. Dyes that interact in different ways will not show a clear and definitive test for a ligand binding in the active site of the protein. In the latter method, the fundamental requirements for the single crystal test involve the ability to produce quantities of suitable single crystals for the ligand binding tests and that the single crystal survives the formation of the protein-ligand complex. As these two requirements are frequently not fulfilled for a chosen protein target, a quicker, more robust method has been desirable for detecting or screening possible interactions between a selected target macromolecule or protein and a suite of possible small molecule ligands.
- It is an object of the present invention to provide a process for process that can be used to detect or screen possible interactions between a selected target macromolecule or protein and one or more possible ligands, e.g., small molecule ligands.
- In accordance with the purposes of the present invention, as embodied and broadly described herein, the present invention provides a process for the evaluation of the binding of ligands to macromolecules using high resolution powder diffraction data including producing a first sample slurry of a selected polycrystalline macromolecule material and a solvent, producing a second sample slurry of a selected polycrystalline macromolecule material, one or more ligands and said solvent, obtaining a high resolution powder diffraction pattern on each of said first sample slurry and said second sample slurry, and, comparing the high resolution powder diffraction pattern of said first sample slurry and the high resolution powder diffraction pattern of said second sample slurry whereby a difference in the high resolution powder diffraction patterns of said polycrystalline macromolecule material in said first sample slurry and said polycrystalline macromolecule material in said second sample slurry beyond expected or measured experimental error provides a positive indication for the formation of a complex between said selected polycrystalline macromolecule material and at least one of said one or more ligands. By “experimental error” is meant the well-understood uncertainties associated with experimentation in general, defined as the variability between observations from experimental units that have been treated identically, including but not limited to such factors as human error, instrument limitations, variations in reagents, errors due to external influences (such as light, heat, dust, etc.), sampling errors, sample variation, and changes in samples based on carrying out an experiment, and the fact that not all measurements have well- or perfectly-defined values.
- The present invention further provides a process of screening, including high throughput screening, of binding of ligands to macromolecules using high resolution powder diffraction data including producing a sample slurry mixture including a selected polycrystalline macromolecule material, a solvent, and a mixture of N ligands, obtaining a high resolution powder diffraction pattern of said sample slurry mixture, comparing the high resolution powder diffraction pattern of said polycrystalline macromolecule material in said sample slurry mixture with a reference of a high resolution powder diffraction pattern of said selected polycrystalline macromolecule material in the absence of any ligands whereby a difference in the high resolution powder diffraction patterns of said polycrystalline macromolecule material in said sample slurry mixture and said selected polycrystalline macromolecule material in the absence of any ligands beyond expected or measured experimental error provides a positive indication for the formation of a complex between said selected polycrystalline macromolecule material and at least one of said mixture of N ligands, dividing said mixture of N ligands into at least two sample slurry groups by forming at least a first sample slurry including said selected polycrystalline macromolecule material, said solvent, and a mixture of selected ligands from among the N ligands, and forming at least a second sample slurry including said selected polycrystalline macromolecule material, said solvent, and a mixture of selected ligands not in said first sample slurry, wherein all of said N ligands are present in at least one of said sample slurry groups, repeating steps of obtaining high resolution powder diffraction patterns, and steps of comparing said high resolution powder diffraction patterns whereby a difference in high resolution powder diffraction patterns between a said polycrystalline macromolecule material in said sample slurry and said selected polycrystalline macromolecule material in the absence of any ligands provides a positive indication for the formation of a complex between said selected polycrystalline macromolecule material and at least one ligand within said sample slurry, and, repeating steps of dividing said mixture of selected ligands for any sample slurry exhibiting a positive indication for the formation of a complex between said selected polycrystalline macromolecule material and at least one ligand within said slurry sample into at least two additional sample slurry groups, steps of obtaining high resolution powder diffraction patterns, and steps of comparing said high resolution powder diffraction patterns until all ligands within said mixture of N ligands that show binding have been identified.
- FIG. 1 shows a comparison plot in accordance with the present invention of a small segment of high resolution x-ray powder diffraction patterns of lysozyme (bottom pattern) in comparison to a lysozyme/N-acetylglucosamine mixture (top pattern) precipated from pH6.0 0.5 M NaCl buffer taken with λ=0.70 Å. The latter pattern has been offset for clarity.
- FIG. 2 shows a comparison plot in accordance with the present invention of a small segment of high resolution x-ray powder diffraction patterns of lysozyme (bottom pattern) in comparison to a lysozyme/N-acetylglucosamine (top pattern) mixture precipated from pH 5.0 0.5 M NaCl buffer taken with λ=0.70 Å. The latter pattern has been offset for clarity.
- The present invention concerns a process that can be used to detect or screen possible interactions between a selected target macromolecule or protein and one or more possible ligands, including small molecule ligands. Certain macromolecules in nature are known to interact with other molecules having a specific 3-dimensional spatial and electronic distribution. Any macromolecule having such specificity can be considered a receptor, whether the macromolecule is an enzyme, a protein, a glycoprotein, an antibody, or an oligonucleotide sequence of DNA, RNA, or the like. The various molecules that associate with such receptors are known as ligands. Small molecule ligands are generally understood to be molecules on the order of about 5,000 Daltons or smaller in size and may be, for example, an organic molecule or a piece or fragment of a larger ligand, such as an antigen or antibody.
- The indication for this interaction or binding is a change in a high resolution powder diffraction pattern of the target protein or macromolecule as compared to the unbound form of the target protein or macromolecule which is the result of a modification of its crystal structure upon formation of a protein-ligand complex. For example, the comparison between patterns can be of the positions of diffraction peaks in the two patterns. In one embodiment, the process is a search approach in which tests of the binding between the target protein or macromolecule and a sequence of ligand mixtures is then used as a rapid means of identifying those ligands that bind to the target protein or macromolecule. One approach can be a binary search approach.
- The screening method of the present invention can be as follows. Two samples of polycrystalline material are produced as slurries. By “slurry” is meant, for example, a suspension of microcrystals of a macromolecule or macromolecule-ligand complex in a liquid. One of the samples includes the target protein or macromolecule and a suitable solvent. The other of the samples includes the target protein or macromolecule, one or more selected ligands and the same solvent as in the first sample. High resolution powder diffraction patterns are obtained for the polycrystalline macromolecule material in each sample. The patterns from the first and second samples are then compared to see if there is any discernable difference between the two sets of diffraction patterns beyond expected or measured experimental error or variation. When there is such a discernable difference between the two sets of diffraction patterns, that is a positive indication for the formation of a complex between the target protein or macromolecule and one or more of the selected ligands. Generally, a simple visual inspection can be used to determine if there is a difference as can be seen in FIG. 1. In another manner, the pattern of the first sample can be inspected or analyzed to determine the positions of the diffraction peaks from the unbound form of the target protein or macromolecule, while the pattern of the second sample can be inspected or analyzed to determine the positions of the diffraction peaks from the target protein or macromolecule in the presence of the one or more selected ligands. Differences in such diffraction peaks can then be used to determine if there is a difference indicating binding of a ligand. This process is readily automated via computerized data processing routines.
- A more detailed screening process for a larger suite of ligands and a single target protein or macromolecule could be as follows. Such a screening process can be a binary search approach as follows or may be other than a binary approach, i.e., division can be into as many sample slurries as desired. In a binary embodiment, a mixture of “N” ligands is produced in a single solution. A preferred embodiment is for the case where N=2 n, i.e., where N is 2, 4, 8, 16, 32 and the like. A target protein or macromolecule is then exposed to the single solution of ligands thereby producing a slurry of polycrystalline material. A screening procedure is conducted wherein high resolution powder diffraction patterns are obtained for the sample. The diffraction pattern is then compared to a reference diffraction pattern from a sample of the unbound form of the target protein or macromolecule. When there is a discernable difference between the two diffraction patterns as described above, that is a positive indication for the formation of a complex between the target protein or macromolecule and one or more of the selected ligands. In one manner, the pattern of the sample is inspected or analyzed to determine the positions of the diffraction peaks from the target protein or macromolecule in the presence of the one or more selected ligands and compared to a reference set of diffraction peaks from a sample of the unbound form of the target protein or macromolecule.
- Where there is a positive indication of an interaction, then there is one or more ligands among the “N” ligands in the mixture that bind to the target protein or macromolecule. In a binary approach, two mixtures of ligands are then formed so that one mixture contains “N/2” of the ligands and the other mixture contains the remaining “N/2” of the ligands. Following the previous procedure, the target protein or macromolecule is exposed to each of the two ligand mixtures to determine which mixture contains one or more ligands that produced the positive indication of binding. This divisional process is repeated until all ligands in the original mixture that show binding to the target protein or macromolecule are identified.
- In such a binary search process, the number of tests required to determine a single ligand with a positive indication of binding with the target protein or macromolecule from amongst a suite of N=2 n ligands is 2(n)+1. For example, if N=64, then the number of tests required would be 13.
- Automation of the steps in this invention will be readily achievable by one skilled in the art of automated processes.
- Powder diffraction from polycrystalline slurries is far more robust because the experimental conditions (solvent pH, ion concentration and the like) for obtaining polycrystalline material is much broader and can be more tightly controlled than for growing large single crystals. In addition, crystal fracture during protein-ligand formation is essentially irrelevant in a powder diffraction experiment as the material is polycrystalline.
- This invention should be useful for screening potential pharmaceutical materials for binding to a protein that was previously identified as a crucial component in a target organism (human, bacterial, viral, etc.). Following this identification of potential activity, further studies can be pursued to determine the usefulness of this material as a drug. In addition, this invention can be used to identify the mode or modes of action for a particular protein by exposing it to a suite of ligands that encompass its possible modes of action. Then, the mode of interaction can be determined by, e.g., examining the results from a single crystal diffraction study of a crystal grown of the protein-ligand complex.
- Recent studies have shown that powder diffraction may be a useful tool for examining protein structures. Powder diffraction patterns can display considerable sensitivity to subtle structural changes via shifts in the diffraction peak positions and changes in intensity. Such studies showed that protein lattice parameter determinations from powder data are perhaps two orders of magnitude more precise than those obtained from typical single crystal experiments and that combined Rietveld refinements (see Rietveld, J. Appl. Crys., vol. 2, pp. 65-71 (1969) and stereochemical restraint refinements can give protein structures of moderate (˜3 Å) resolution.
- For the study of protein/ligand complexes, powder diffraction offers a distinct advantage over single crystal work in its complete immunity to crystal fracture or even a phase change that may accompany complex formation. Moreover, rapid formation of a polycrystalline precipitate allows possible exploration of initial complex formation under a wide variety of conditions not accessible in slow soaking or single crystal growth experiments. The use of high resolution X-ray powder diffraction for protein/ligand structure determination in a study of the binding of N-acetyglucosamine to chicken egg lysozyme has now been demonstrated.
- Previous high-resolution X-ray powder diffraction studies with metmyoglobin and T 3R3 Zn insulin complexes used samples obtained by grinding previously crystallized protein in its mother liquor and yielded material with extremely sharp diffraction peaks and little or no sample broadening.
- In this embodiment of the present invention, the lattice parameters of lysozyme and (α-NAG/lysozyme complex (Table 1) have been determined with unprecedented precision via powder diffraction. The precision obtained here approaches one part in 80,000 and is the result of Rietveld refinement fitting of the entire powder diffraction profile and the extreme sharpness of the peaks. Similar precision was obtained in earlier powder diffraction studies of metmyoglobin and Zn insulin complexes (see Von Dreele, J. Appl. Cryst., vol. 32, pp. 1084-1089 (1999) and Von Dreele et al., Acta Cryst., vol. D56, pp. 1549-1553 (2000)). Consequently small changes in these values with pH and complex formation are readily apparent and can even be discerned from a simple visual comparison (FIGS. 1 & 2). Formation of the α-NAG/lysozyme complex from pH 6.0 0.5M NaCl was marked by easily visible changes in the powder diffraction patterns (FIG. 1) and significant changes in the lattice parameters. For the complex, a is smaller by 0.21% and c larger by 0.49% compared to those of the apo-protein precipitated from the same buffer. This change upon complex formation is consistent with the lower precision single crystal values obtained by Perkins et al., Biochem. J., vol. 173, pp. 607-616 (1978) and, interestingly, those obtained by Cheetham et al. J. Mol. Biol., vol. 224, pp. 613-628 (1992) for the NAG 3/lysozyme complex. The precipitate from a NAG/lysozyme mixture in pH 5.0 0.5M NaCl showed no visible change in the powder pattern (FIG. 2) from that of pure lysozyme prepared from the same solvent and the lattice parameters are also essentially unchanged (a smaller by 0.06% and c larger by 0.15%).
- Clearly, as observed earlier for metmyoglobin and T 3R3 Zn prepared by grinding single crystals, polycrystalline lysozyme and NAG/lysozyme powders, prepared in this case by rapid precipitation, consist of essentially defect free crystallites that are a few microns across. These dimensions suggest that the crystallites are only a few hundred protein unit cells in extent which, when coupled with the relatively weak binding between adjacent molecules, is insufficient to retain point and line defects at ambient temperature. Consequently, powder diffraction patterns of these materials give diffraction peaks that are as sharp as can be obtained from a given diffraction instrument; this may be a common feature of ambient temperature protein powder diffraction patterns. In essence, proteins are “perfect” powders for diffraction thus ensuring application of this invention to a wide variety of proteins. Here, the extreme sharpness of these patterns arose from the uniform and easily controlled precipitation conditions and allowed easy discernment of the small structural changes associated with protein/ligand complex formation and ready discrimination from cases where no complex is formed. Moreover, the quality of the powder diffraction pattern was sufficient to determine the detailed structural features of the protein/ligand complex. Thus, high-resolution powder diffraction can facilitate the screening for protein/ligand interactions and may facilitate the determination of their resulting structures under a wide variety of conditions.
- The present invention is more particularly described in the following example which is intended as illustrative only, since numerous modifications and variations will be apparent to those skilled in the art.
- Chicken egg lysozyme (EC 3.2.1.17, FisherBiotech, 3X crystallized, lot Nos. 995417-12 and 996924-12) and N-acetylglucosamine (NAG, ICN Biomedicals, Inc. lot No. R9745), pH 6.0 0.05M Na 2HPO4/KH2PO4 buffer (Fisher Sci.), pH 5.0 0.05M KHphthalate/NaOH buffer (Hydrion™, Aldrich Chem.) and NaCl (“Certified for Biological Use”, Fisher Sci.) were used as received. In a typical sample preparation, a polycrystalline slurry was made by combining ˜20 mg lysozyme (1.4 μmol), about 10 mg of NAG (45 μmol) and 200 μl of 0.5M NaCl pH 6.0 buffer with an agate mortar and pestle. Polycrystalline precipitate formed within a few seconds. The slurry was loaded into a 1.5 mm diameter glass capillary, and centrifuged to pack the slurry. Excess mother liquor was removed and the capillary flame sealed to prevent subsequent solvent evaporation. In a similar way, a polycrystalline sample of unbound lysozyme in pH 6.0 0.5M NaCl buffer was prepared. Similar samples with pH 5.0 0.5M NaCl buffer were also prepared. Samples were about 8 mm long. As each sample was prepared, X-ray powder diffraction data were immediately collected at room temperature (23° C.) on beam line X3bl at the National Synchrotron Light Source, Brookhaven National Laboratory, equipped with a double Si(111) monochromator and a Ge(111) analyser; the sample was spun during data collection to ensure good powder averaging. Details of the data collections are given in Table 1.
TABLE 1 Crystallographic data for N-acetyl-D-glucosamine/ lysozyme complexes* NAG/ NAG/ Material lysozyme lysozyme lysozyme lysozyme Crystal data: Space group P43212 P43212 P43212 P43212 a(Å) 79.1317(11) 78.9631(10) 78.5689(15) 78.5240(14) c(Å) 38.0297(10) 38.2151(10) 38.5134(15) 38.5731(14) V(Å3) 238135(8) 238277(9) 237746(12) 237842(12) Powder data collection: Buffer pH 6.00 6.00 5.00 5.00 Measured pH 5.2 5.1 4.8 4.8 λ (Å) 0.699970(1) 0.699842(1) 0.700030(1) 0.700030(1) 2Θ range (°) 1.0-13.580 1.0-13.498 1.0-13.994 1.0-13.698 Δ2Θ (°) 0.002 0.002 0.002 0.002 Steps 6291 6250 6497 6350 Step time (s) 4.0-11.25 4.0-11.13 4.0-12.04 4.0-11.51 # a LAZAR Research Laboratories PHR-146 Micro Combination electrode calibrated with pH 4.00 and pH 7.00 standard buffers (Fisher Sci.). Wavelength # calibrations were obtained from the fitted positions of six reflections from a NIST SRM1976 alumina plate. Data collection step count # times were determined by the following algorithm: for 2Θ < 5° t = 4s; for 2Θ > 5° t = 6.4691 −0.9877 #(2Θ) + 0.0988(2Θ)2s. - Visual comparison of the diffraction patterns obtained from lysozyme and NAG/lysozyme polycrystalline slurries formed in the pH 6.0 0.5M NaCl buffer (FIG. 1) clearly show that a structural modification has occurred associated with the formation of a NAG/lysozyme complex. The patterns show differences in peak positions, which arise from lattice parameter changes, and differences in intensity associated with the crystal structure modification. There were no changes evident in a comparison of the powder patterns of lysozyme and NAG/lysozyme slurries prepared with pH 5.0 0.5M NaCl buffer (FIG. 2).
- Although the present invention has been described with reference to specific details, it is not intended that such details should be regarded as limitations upon the scope of the invention, except as and to the extent that they are included in the accompanying claims.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/160,367 US20030059843A1 (en) | 2001-05-31 | 2002-05-31 | High throughput screening of ligand binding to macromolecules using high resolution powder diffraction |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/871,527 US7130747B1 (en) | 2001-05-31 | 2001-05-31 | High throughput screening of ligand binding to macromolecules using high resolution powder diffraction |
| US10/160,367 US20030059843A1 (en) | 2001-05-31 | 2002-05-31 | High throughput screening of ligand binding to macromolecules using high resolution powder diffraction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/871,527 Continuation-In-Part US7130747B1 (en) | 2001-05-31 | 2001-05-31 | High throughput screening of ligand binding to macromolecules using high resolution powder diffraction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030059843A1 true US20030059843A1 (en) | 2003-03-27 |
Family
ID=25357650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/871,527 Expired - Fee Related US7130747B1 (en) | 2001-05-31 | 2001-05-31 | High throughput screening of ligand binding to macromolecules using high resolution powder diffraction |
| US10/160,367 Abandoned US20030059843A1 (en) | 2001-05-31 | 2002-05-31 | High throughput screening of ligand binding to macromolecules using high resolution powder diffraction |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/871,527 Expired - Fee Related US7130747B1 (en) | 2001-05-31 | 2001-05-31 | High throughput screening of ligand binding to macromolecules using high resolution powder diffraction |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US7130747B1 (en) |
| AU (1) | AU2002344310A1 (en) |
| WO (1) | WO2002097396A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE530896T1 (en) * | 2006-05-05 | 2011-11-15 | Shire Int Licensing Bv | ASSAY FOR LANTHAN HYDROXYCARBONATE |
| CN105571915B (en) * | 2015-12-17 | 2018-03-13 | 扬州大学 | Fast preparation method for hydrogen storage material synchrotron radiation X ray sample |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434796A (en) * | 1993-06-30 | 1995-07-18 | Daylight Chemical Information Systems, Inc. | Method and apparatus for designing molecules with desired properties by evolving successive populations |
| US5571902A (en) * | 1993-07-29 | 1996-11-05 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| US6128582A (en) * | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
| US6177280B1 (en) * | 1996-12-24 | 2001-01-23 | Xinjian Yan | Ricin inhibitors and methods for use thereof |
| US6229010B1 (en) * | 1997-07-02 | 2001-05-08 | Merck & Co., Inc. | Polymorphic form of a tachykinin receptor antagonist |
| US6230102B1 (en) * | 1997-04-04 | 2001-05-08 | Massachusetts Institute Of Technology | Computer system and process for identifying a charge distribution which minimizes electrostatic contribution to binding at binding between a ligand and a molecule in a solvent and uses thereof |
| US6297021B1 (en) * | 1998-03-06 | 2001-10-02 | Abbott Laboratories | Ligand screening and design by X-ray crystallography |
| US6327334B1 (en) * | 1999-11-18 | 2001-12-04 | Uop Llc | Method of rapidly screening X-ray powder diffraction patterns |
| US20030198997A1 (en) * | 2002-04-19 | 2003-10-23 | The Regents Of The University Of California | Analysis of macromolecules, ligands and macromolecule-ligand complexes |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3373803B2 (en) * | 1999-05-28 | 2003-02-04 | 科学技術振興事業団 | Combinatorial X-ray diffractometer |
-
2001
- 2001-05-31 US US09/871,527 patent/US7130747B1/en not_active Expired - Fee Related
-
2002
- 2002-05-31 WO PCT/US2002/017274 patent/WO2002097396A2/en not_active Ceased
- 2002-05-31 US US10/160,367 patent/US20030059843A1/en not_active Abandoned
- 2002-05-31 AU AU2002344310A patent/AU2002344310A1/en not_active Abandoned
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434796A (en) * | 1993-06-30 | 1995-07-18 | Daylight Chemical Information Systems, Inc. | Method and apparatus for designing molecules with desired properties by evolving successive populations |
| US5571902A (en) * | 1993-07-29 | 1996-11-05 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| US6128582A (en) * | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
| US6177280B1 (en) * | 1996-12-24 | 2001-01-23 | Xinjian Yan | Ricin inhibitors and methods for use thereof |
| US6230102B1 (en) * | 1997-04-04 | 2001-05-08 | Massachusetts Institute Of Technology | Computer system and process for identifying a charge distribution which minimizes electrostatic contribution to binding at binding between a ligand and a molecule in a solvent and uses thereof |
| US6229010B1 (en) * | 1997-07-02 | 2001-05-08 | Merck & Co., Inc. | Polymorphic form of a tachykinin receptor antagonist |
| US6297021B1 (en) * | 1998-03-06 | 2001-10-02 | Abbott Laboratories | Ligand screening and design by X-ray crystallography |
| US6327334B1 (en) * | 1999-11-18 | 2001-12-04 | Uop Llc | Method of rapidly screening X-ray powder diffraction patterns |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20030198997A1 (en) * | 2002-04-19 | 2003-10-23 | The Regents Of The University Of California | Analysis of macromolecules, ligands and macromolecule-ligand complexes |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002097396A3 (en) | 2003-05-01 |
| US7130747B1 (en) | 2006-10-31 |
| WO2002097396A2 (en) | 2002-12-05 |
| AU2002344310A1 (en) | 2002-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Renaud et al. | Biophysics in drug discovery: impact, challenges and opportunities | |
| Ilchenko et al. | Fast and quantitative 2D and 3D orientation mapping using Raman microscopy | |
| US7061605B2 (en) | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions | |
| US7469036B2 (en) | Analysis of macromolecules, ligands and macromolecule-ligand complexes | |
| Saudagar et al. | Advanced spectroscopic methods to study biomolecular structure and dynamics | |
| JP2004526949A (en) | Apparatus and method for crystal identification by in situ X-ray diffraction | |
| US20030138940A1 (en) | Apparatus and method for high-throughput preparation and characterization of compositions | |
| US20160077099A1 (en) | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability | |
| EP1644095B1 (en) | Method and apparatus for detecting chemical binding | |
| Von Dreele | Binding of N-acetylglucosamine to chicken egg lysozyme: a powder diffraction study | |
| Takizawa et al. | While the revolution will not be crystallized, biochemistry reigns supreme | |
| Carpentier et al. | Advances in spectroscopic methods for biological crystals. 2. Raman spectroscopy | |
| Spiliopoulou et al. | Rietveld refinement for macromolecular powder diffraction | |
| US20030059843A1 (en) | High throughput screening of ligand binding to macromolecules using high resolution powder diffraction | |
| Ma et al. | Near-infrared and mid-infrared Fourier transform vibrational circular dichroism of proteins in aqueous solution | |
| Margiolaki | Macromolecular powder diffraction | |
| Tuschel et al. | Site occupancy of Ti4+-doped ZrGeO4 and HfGeO4 probed by Raman spectroscopy | |
| Hofer et al. | Continuous Serial Electron Diffraction for High Quality Protein Structures | |
| Stingaciu | Study of protein dynamics via neutron spin echo spectroscopy | |
| EP1576375B1 (en) | Synthesis and screening of ligands using x-ray crystallography | |
| Asanov et al. | Intrinsic fluorescence as a potential rapid scoring tool for protein crystals | |
| Font Bardia et al. | X-ray single crystal and powder diffraction: possibilities and applications | |
| WO2002097397A2 (en) | Analysis of macromolecules, ligands and macromolecule-ligand complexes | |
| US20010046684A1 (en) | Methods of structure-based drug design using MS/MNR | |
| Margiolaki | Crystal screening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE, NEW Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VON DREELE, ROBERT B.;REEL/FRAME:013553/0356 Effective date: 20021007 |
|
| AS | Assignment |
Owner name: ENERGY, U.S. DEPARTMENT OF, DISTRICT OF COLUMBIA Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SANDIA CORPORATION;REEL/FRAME:013947/0146 Effective date: 20021010 |
|
| AS | Assignment |
Owner name: LOS ALAMOS NATIONAL SECURITY, LLC, NEW MEXICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE;REEL/FRAME:017918/0931 Effective date: 20060424 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |